Three things to know:
1. The study will enroll 320 people aged 30 to 70 years old who have been diagnosed with leg pain from a herniated lumbar disc.
2. A Phase 3 study in Japan demonstrated that an injection of the drug into the nucleus pulposus reduced nerve root by decreasing pressure and volume of herniation, resulting in less pain.
3. SI-6603, the study drug, has yet to be approved for use in the U.S. by the FDA.
More articles on spine:
Zimmer Biomet replaces retiring CFO
Stryker expands overseas & more: 6 device company key notes
Pacira appoints former Johnson & Johnson exec Max Reinhardt president
